Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | IBI3001 |
Synonyms | |
Therapy Description |
IBI3001 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting CD276 (B7-H3) and EGFR linked to Exatecan, which potentially decreases tumor growth (Cancer Res (2024) 84 (7_Supplement): LB055). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IBI3001 | IBI-3001|IBI 3001 | CD276 Antibody 12 EGFR Antibody 56 | IBI3001 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting CD276 (B7-H3) and EGFR linked to Exatecan, which potentially decreases tumor growth (Cancer Res (2024) 84 (7_Supplement): LB055). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06349408 | Phase Ib/II | IBI3001 | IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |